Jiangsu Cowin Biotech Co. Ltd. A
Jiangsu CoWin Biotech Co., Ltd. engages in the research and development, production, and sale of biological products in China. The company provides molecular diagnostic raw material enzymes, nucleic acid collection and protection agents, nucleic acid extraction and purification kits, molecular diagnostic testing reagents, etc. It also offers medical device products, nucleic acid collection and pr… Read more
Jiangsu Cowin Biotech Co. Ltd. A (688426) - Total Liabilities
Latest total liabilities as of June 2025: CN¥145.32 Million CNY
Based on the latest financial reports, Jiangsu Cowin Biotech Co. Ltd. A (688426) has total liabilities worth CN¥145.32 Million CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jiangsu Cowin Biotech Co. Ltd. A - Total Liabilities Trend (2020–2024)
This chart illustrates how Jiangsu Cowin Biotech Co. Ltd. A's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jiangsu Cowin Biotech Co. Ltd. A Competitors by Total Liabilities
The table below lists competitors of Jiangsu Cowin Biotech Co. Ltd. A ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SUI Group Holdings Limited
NASDAQ:SUIG
|
USA | $24.04 Million |
|
Taaleri Oyj
HE:TAALA
|
Finland | €84.96 Million |
|
XSpring Capital Public Company Limited
BK:XPG
|
Thailand | ฿362.49 Million |
|
Quess Corp Limited
NSE:QUESS
|
India | ₹19.36 Billion |
|
Ca Toulouse 31 CCI
PA:CAT31
|
France | €14.30 Billion |
|
Hap Seng Plantations Holdings Bhd
KLSE:5138
|
Malaysia | RM501.99 Million |
|
Taisun Enterprise Co Ltd
TW:1218
|
Taiwan | NT$2.44 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Jiangsu Cowin Biotech Co. Ltd. A's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 14.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jiangsu Cowin Biotech Co. Ltd. A's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jiangsu Cowin Biotech Co. Ltd. A (2020–2024)
The table below shows the annual total liabilities of Jiangsu Cowin Biotech Co. Ltd. A from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥131.79 Million | -7.62% |
| 2023-12-31 | CN¥142.67 Million | -12.80% |
| 2022-12-31 | CN¥163.60 Million | +62.77% |
| 2021-12-31 | CN¥100.51 Million | +76.20% |
| 2020-12-31 | CN¥57.04 Million | -- |